Skip to main content
Top
Published in: Abdominal Radiology 10/2020

01-10-2020 | Pelvis

Differentiation of borderline tumors from type I ovarian epithelial cancers on CT and MR imaging

Authors: Sihua Yang, Huan Tang, Fuxia Xiao, Jingqi Zhu, Ting Hua, Guangyu Tang

Published in: Abdominal Radiology | Issue 10/2020

Login to get access

Abstract

Purpose

To investigate the value of CT and MR imaging features in differentiating borderline ovarian tumor (BOT) from type I ovarian epithelial cancer (OEC), which could be significant for suitable clinical treatment and assessment of the prognosis of the patient.

Methods

Thirty-three patients with BOTs and 35 patients with type I OECs proven by pathology were retrospectively evaluated. The clinico-pathological information (age, premenopausal status, CA-125, and Ki-67) and imaging characteristics were compared between two groups of ovarian tumors. The diagnostic performance of the imaging features was evaluated using receiver operating characteristic analysis. The best predictor variables for type I EOCs were recognized via multivariate analyses.

Results

BOTs are more likely to involve younger patients and frequently show lower CA-125 values and lower proliferation indices (Ki-67 < 15%) than type I OECs. Compared with type I OECs, BOTs were more often purely cystic (15/33, 45.45% vs. 1/35, 2.86%; p < 0.001) and displayed less frequent mural nodules (16/33, 48.48% vs. 28/35, 80.00%; p = 0.007), less frequently unclear margin (3/33, 9.09% vs. 11/35, 31.43%; p = 0.023), smaller solid portion (0.56 ± 2.66 vs. 4.51 ± 3.88; p < 0.001), and thinner walls (0.3 ± 0.17 vs. 0.55 ± 0.24; p < 0.001). The maximum wall thickness presented the largest area under the curve (AUC, 0.848). Multivariate analysis revealed that the solid portion size (OR 10.822, p = 0.002) and maximum wall thickness (OR 9.130, p = 0.001) were independent indicators for the differential diagnosis between the two groups of lesions.

Conclusion

The solid portion size and maximum wall thickness significantly influenced the classification of the two groups of ovarian tumors.
Literature
1.
go back to reference Authors N (1971) Classification and Staging of Malignant Tumours in the Female Pelvis. Acta Obstet Gyn Scan 50(1):1-7CrossRef Authors N (1971) Classification and Staging of Malignant Tumours in the Female Pelvis. Acta Obstet Gyn Scan 50(1):1-7CrossRef
2.
go back to reference Naqvi J, Nagaraju E, Ahmad S (2015) MRI appearances of pure epithelial papillary serous borderline ovarian tumours. Clin Radiol 70(4):424-432CrossRef Naqvi J, Nagaraju E, Ahmad S (2015) MRI appearances of pure epithelial papillary serous borderline ovarian tumours. Clin Radiol 70(4):424-432CrossRef
3.
go back to reference Kurman RJ, Shih IM (2016) The Dualistic Model of Ovarian Carcinogenesis Revisited, Revised, and Expanded. Am J Pathol 186(4):733-747CrossRef Kurman RJ, Shih IM (2016) The Dualistic Model of Ovarian Carcinogenesis Revisited, Revised, and Expanded. Am J Pathol 186(4):733-747CrossRef
4.
go back to reference Shih IM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511-1518CrossRef Shih IM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511-1518CrossRef
5.
go back to reference Koshiyama M, Matsumura N, Konishi I (2014) Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. Biomed Res Int 2014(5-6):934261 Koshiyama M, Matsumura N, Konishi I (2014) Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. Biomed Res Int 2014(5-6):934261
6.
go back to reference Singer G, Kurman RJ, Chang HW et al (2002) Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. Am J Pathol 160(4): 1223-1228CrossRef Singer G, Kurman RJ, Chang HW et al (2002) Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma. Am J Pathol 160(4): 1223-1228CrossRef
7.
go back to reference Li HM, Qiang JW, Ma FH et al (2017) The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors. J Ovarian Res 10(1):4CrossRef Li HM, Qiang JW, Ma FH et al (2017) The value of dynamic contrast–enhanced MRI in characterizing complex ovarian tumors. J Ovarian Res 10(1):4CrossRef
8.
go back to reference Foti PV, Attinà G, Spadola S et al (2016) MR imaging of ovarian masses: classification and differential diagnosis. Insights into Imaging 7(1):21-41CrossRef Foti PV, Attinà G, Spadola S et al (2016) MR imaging of ovarian masses: classification and differential diagnosis. Insights into Imaging 7(1):21-41CrossRef
9.
go back to reference Kurman RJ (2014) International Agency for Research on Cancer, World Health Organization, WHO Classification of Tumours of Female Reproductive Organs, 4th ed., International Agency for Research on Cancer, Lyon Kurman RJ (2014) International Agency for Research on Cancer, World Health Organization, WHO Classification of Tumours of Female Reproductive Organs, 4th ed., International Agency for Research on Cancer, Lyon
10.
go back to reference Gershenson DM (2017) Management of borderline ovarian tumours. Best Pract Res Cl Ob 41:49-59CrossRef Gershenson DM (2017) Management of borderline ovarian tumours. Best Pract Res Cl Ob 41:49-59CrossRef
11.
go back to reference Khalifeh I, Munkarah AR, Schimp V et al (2005) The Impact of C-kit and Ki-67 Expression on Patients Prognosis in Advanced Ovarian Serous Carcinoma. Int J Gynecol Pathol 24(3):228-234CrossRef Khalifeh I, Munkarah AR, Schimp V et al (2005) The Impact of C-kit and Ki-67 Expression on Patients Prognosis in Advanced Ovarian Serous Carcinoma. Int J Gynecol Pathol 24(3):228-234CrossRef
12.
go back to reference Pannu HK, Ma W, Zabor EC et al (2013) Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. ISRN Obstet Gynecol 2013(7): 979345–979353PubMed Pannu HK, Ma W, Zabor EC et al (2013) Enhancement of ovarian malignancy on clinical contrast enhanced MRI studies. ISRN Obstet Gynecol 2013(7): 979345–979353PubMed
13.
go back to reference Liu D, Zhang L, Indima N et al (2017) CT and MRI findings of type I and type II epithelial ovarian cancer. Eur J Radiol 90:225-233CrossRef Liu D, Zhang L, Indima N et al (2017) CT and MRI findings of type I and type II epithelial ovarian cancer. Eur J Radiol 90:225-233CrossRef
14.
go back to reference Sadlecki P, Jozwicki J, Antosik P et al (2018) Expression of selected epithelial–mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers. Tumor Biol. DOI: 1010428318784807 Sadlecki P, Jozwicki J, Antosik P et al (2018) Expression of selected epithelial–mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers. Tumor Biol. DOI: 1010428318784807
15.
go back to reference Gąsiorowska E, Michalak M, Warchoł W et al (2015) Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Ginekol Pol 86(2):88-93CrossRef Gąsiorowska E, Michalak M, Warchoł W et al (2015) Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Ginekol Pol 86(2):88-93CrossRef
16.
go back to reference Sadlecki P, Walentowicz-Sadlecka M, Grabiec M (2017) Molecular diagnosis in type I epithelial ovarian cancer. Ginekol Pol 88(12):692-697CrossRef Sadlecki P, Walentowicz-Sadlecka M, Grabiec M (2017) Molecular diagnosis in type I epithelial ovarian cancer. Ginekol Pol 88(12):692-697CrossRef
17.
go back to reference Li HM, Feng F, Qiang JW et al (2018) Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors. Abdom Radiol 43(11):3132-3141CrossRef Li HM, Feng F, Qiang JW et al (2018) Quantitative dynamic contrast-enhanced MR imaging for differentiating benign, borderline, and malignant ovarian tumors. Abdom Radiol 43(11):3132-3141CrossRef
18.
go back to reference Zhao SH, Qiang JW, Zhang GF et al (2014) Diffusion-weighted MR imaging for differentiating borderline from malignant epithelial tumours of the ovary: pathological correlation. Eur Radiol 24(9):2292-2299CrossRef Zhao SH, Qiang JW, Zhang GF et al (2014) Diffusion-weighted MR imaging for differentiating borderline from malignant epithelial tumours of the ovary: pathological correlation. Eur Radiol 24(9):2292-2299CrossRef
19.
go back to reference Chen J, Chang C, Huang HC et al (2015) Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model. Taiwan J Obstet Gyne 54(4):398-402CrossRef Chen J, Chang C, Huang HC et al (2015) Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model. Taiwan J Obstet Gyne 54(4):398-402CrossRef
20.
go back to reference Desouza NM, O”Neill R, Mcindoe GA et al (2005) Borderline Tumors of the Ovary: CT and MRI Features and Tumor Markers in Differentiation from Stage I Disease. AJR Am J Roentgenol 184(3):999-1003CrossRef Desouza NM, O”Neill R, Mcindoe GA et al (2005) Borderline Tumors of the Ovary: CT and MRI Features and Tumor Markers in Differentiation from Stage I Disease. AJR Am J Roentgenol 184(3):999-1003CrossRef
21.
go back to reference Giurgea LN, Ungureanu C, Mihailovici MS (2012) The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryo 53(4):967-973 Giurgea LN, Ungureanu C, Mihailovici MS (2012) The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom J Morphol Embryo 53(4):967-973
22.
go back to reference Zhang G, Yao W, Sun T et al (2019) Magnetic resonance imaging in categorization of ovarian epithelial cancer and survival analysis with focus on apparent diffusion coefficient value: correlation with Ki-67 expression and serum cancer antigen-125 level. J Ovarian Res. DOI: 10.1186/s13048-019-0534-0CrossRefPubMedPubMedCentral Zhang G, Yao W, Sun T et al (2019) Magnetic resonance imaging in categorization of ovarian epithelial cancer and survival analysis with focus on apparent diffusion coefficient value: correlation with Ki-67 expression and serum cancer antigen-125 level. J Ovarian Res. DOI: 10.1186/s13048-019-0534-0CrossRefPubMedPubMedCentral
23.
go back to reference Denewar FA, Takeuchi M, Urano M et al (2017) Multiparametric MRI for differentiation of borderline ovarian tumors from stage I malignant epithelial ovarian tumors using multivariate logistic regression analysis. Eur J of Radiol 91:116-123CrossRef Denewar FA, Takeuchi M, Urano M et al (2017) Multiparametric MRI for differentiation of borderline ovarian tumors from stage I malignant epithelial ovarian tumors using multivariate logistic regression analysis. Eur J of Radiol 91:116-123CrossRef
24.
go back to reference Nougaret S, Lakhman Y, Molinari N, et al (2018) CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas. AJR Am J Roentgenol 210(4):918-926CrossRef Nougaret S, Lakhman Y, Molinari N, et al (2018) CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas. AJR Am J Roentgenol 210(4):918-926CrossRef
25.
go back to reference Ghossain MA, Buy JN, Lignères C et al (1991) Epithelial tumors of the ovary: comparison of MR and CT findings. Radiology 181(3):863-870CrossRef Ghossain MA, Buy JN, Lignères C et al (1991) Epithelial tumors of the ovary: comparison of MR and CT findings. Radiology 181(3):863-870CrossRef
26.
go back to reference Jung SE, Lee JMRHASE, Byun JY, et al. (2002) CT and MR Imaging of Ovarian Tumors with Emphasis on Differential Diagnosis. Radiographics 22(6):1305–1325CrossRef Jung SE, Lee JMRHASE, Byun JY, et al. (2002) CT and MR Imaging of Ovarian Tumors with Emphasis on Differential Diagnosis. Radiographics 22(6):1305–1325CrossRef
27.
go back to reference Jang YJ, Kim JK, Park SB et al (2007) Variable CT Findings of Epithelial Origin Ovarian Carcinoma According to the Degree of Histologic Differentiation. Korean J Radiol 8(2):120-126CrossRef Jang YJ, Kim JK, Park SB et al (2007) Variable CT Findings of Epithelial Origin Ovarian Carcinoma According to the Degree of Histologic Differentiation. Korean J Radiol 8(2):120-126CrossRef
28.
go back to reference Li YA, Qiang JW, Ma FH et al (2018) MRI features and score for differentiating borderline from malignant epithelial ovarian tumors. Eur J Radiol 98:136-142CrossRef Li YA, Qiang JW, Ma FH et al (2018) MRI features and score for differentiating borderline from malignant epithelial ovarian tumors. Eur J Radiol 98:136-142CrossRef
29.
go back to reference Mimura R, Kato F, Tha KK et al (2016) Comparison between borderline ovarian tumors and carcinomas using semi-automated histogram analysis of diffusion-weighted imaging: focusing on solid components. Jpn J Radiol 34(3):229-237CrossRef Mimura R, Kato F, Tha KK et al (2016) Comparison between borderline ovarian tumors and carcinomas using semi-automated histogram analysis of diffusion-weighted imaging: focusing on solid components. Jpn J Radiol 34(3):229-237CrossRef
30.
go back to reference Kurata Y, Kido A, Moribata Y et al (2016) Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumour from endometriosis-related malignant ovarian tumour. Eur Radiol 27(4):1695-1703CrossRef Kurata Y, Kido A, Moribata Y et al (2016) Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumour from endometriosis-related malignant ovarian tumour. Eur Radiol 27(4):1695-1703CrossRef
Metadata
Title
Differentiation of borderline tumors from type I ovarian epithelial cancers on CT and MR imaging
Authors
Sihua Yang
Huan Tang
Fuxia Xiao
Jingqi Zhu
Ting Hua
Guangyu Tang
Publication date
01-10-2020
Publisher
Springer US
Published in
Abdominal Radiology / Issue 10/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02467-w

Other articles of this Issue 10/2020

Abdominal Radiology 10/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.